Abbisko's vision is to discover and develop novel and differentiated therapies in oncology and beyond to address critical unmet medical needs for patients in China and worldwide.Founded in 2016, Abbisko was listed on HKEX in 2021.Abbisko has >230 employees today and 5 operation sites in China. World-class discovery engine has been established by industry veterans, validated by global pharma partners, and endorsed by blue-chip global investors.We have innovative pipeline with multiple global leading assets covering both precision oncology and immuno-oncology.7 programs are in clinical stage, 3 in PoC stage, and our leading CSF-1R inhibitor program is entering Ph3 study. Abbisko has experience for partnering with MNCs and Biotechs. Our programes are open for partnering, with flexibility of partnering models.